Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by Introgen Therapeutics.
Recruitment status was  Recruiting
Information provided by:
Introgen Therapeutics Identifier:
First received: July 11, 2002
Last updated: March 28, 2008
Last verified: March 2008
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) will be compared to methotrexate in patients who have failed surgery, radiotherapy and chemotherapy with platinum or taxanes.

Condition Intervention Phase
Carcinoma, Squamous Cell
Genetic: INGN 201
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Introgen Therapeutics:


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • 18 years or older
  • Not eligible for surgery
  • Must have had radiation and chemotherapy treatments
  • No prior methotrexate treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00041613

Contact: Introgen Therapeutics, Inc. 866.631.4646
Contact: Therapeutics, Inc.

United States, Colorado
Unversity of Colorado Cancer Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Brittney Hines    720-848-0678   
Principal Investigator: Madeleine Kane, MD         
United States, Kentucky
Norton Healthcare Pavilion Recruiting
Louisville, Kentucky, United States, 40202
Contact: Daniela Neamtu    502-629-4679   
Principal Investigator: John Hamm, MD         
United States, Maryland
Cancer Center of GBMC Recruiting
Baltimore, Maryland, United States, 21204
Contact: Lauren Titus    443-849-3285   
Principal Investigator: Marshall Levine, MD         
United States, South Carolina
WJB Dorn VA Medical Center Recruiting
Columbia, South Carolina, United States, 29209
Contact: Justin Reynolds    803-776-4000 ext 6074   
Principal Investigator: William Hrushesky, MD         
United States, Texas
Mary Crowley Medical Research Center Recruiting
Dallas, Texas, United States, 75201
Contact: Arlen Waclawczyk    214-658-1985   
Principal Investigator: John Nemunaitis, MD         
Sponsors and Collaborators
Introgen Therapeutics
Study Director: Kerstin Menander, MD
Study Chair: Julie L Sicam, MT (ASCP) MSHS
  More Information

No publications provided Identifier: NCT00041613     History of Changes
Obsolete Identifiers: NCT00040703
Other Study ID Numbers: T301
Study First Received: July 11, 2002
Last Updated: March 28, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Introgen Therapeutics:
Refractory Squamous Cell Carcinoma of the Head and Neck

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell processed this record on November 27, 2015